Imatinib Torrent Pharma (Uk)

Imatinib, the active ingredient in Imatinib Torrent Pharma (Uk), is a tyrosine kinase inhibitor presented as a tablet for oral use. It treats chronic myeloid leukemia, Philadelphia chromosome‑positive acute lymphoblastic leukemia and gastrointestinal stromal tumor in adult patients.

GNH USA supplies Imatinib Torrent Pharma (Uk) as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Imatinib is a targeted tyrosine‑kinase inhibitor used in several hematologic and solid‑tumor indications. - Chronic myeloid leukemia (CML): suppresses BCR‑ABL driven proliferation and improves long‑term survival. - Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): adds to remission rates when combined with chemotherapy. - Gastrointestinal stromal tumor (GIST): blocks c‑KIT signaling to reduce tumor growth and recurrence.

Adverse reactions may occur with Imatinib therapy and are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Edema: peripheral swelling, especially of the ankles. - Fatigue: generalized tiredness affecting daily activities. - Diarrhea: loose stools, often transient.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or jaundice requiring monitoring. - Cardiotoxicity: rare cases of left ventricular dysfunction. - Severe neutropenia: marked reduction in white blood cells increasing infection risk. - Pulmonary hypertension: uncommon but potentially life‑threatening lung pressure elevation.

Before initiating Imatinib, clinicians should assess patient history and monitor relevant parameters. - Baseline liver function: check ALT, AST, bilirubin levels. - Cardiac evaluation: perform ECG if pre‑existing heart disease. - Hematologic monitoring: CBC to detect neutropenia or anemia. - Drug interactions: review concomitant medications for CYP3A4 modulators. - Pregnancy and lactation: avoid use unless benefits outweigh risks. - Store at ambient temperature: keep below 25 °C in original container, protect from moisture and direct sunlight.

Imatinib may interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampicin, carbamazepine): markedly reduce Imatinib exposure. - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): increase plasma levels and toxicity risk.

Moderate Interactions (Monitor Closely): - Acid‑reducing agents (e.g., proton pump inhibitors, antacids): may lower absorption. - Anticoagulants (e.g., warfarin): potential for altered INR. - Vaccines: live attenuated vaccines should be avoided during therapy.